Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.

Broad-spectrum inhibition of HIV-1 by a monoclonal antibody directed against a gp120-induced epitope of CD4.

Burastero SE, Frigerio B, Lopalco L, Sironi F, Breda D, Longhi R, Scarlatti G, Canevari S, Figini M, Lusso P.

PLoS One. 2011;6(7):e22081. doi: 10.1371/journal.pone.0022081.

3.
4.

Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.

Earl PL, Broder CC, Long D, Lee SA, Peterson J, Chakrabarti S, Doms RW, Moss B.

J Virol. 1994 May;68(5):3015-26.

5.

Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120.

Matsushita S, Matsumi S, Yoshimura K, Morikita T, Murakami T, Takatsuki K.

J Virol. 1995 Jun;69(6):3333-40.

6.
7.

Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure.

Ditzel HJ, Binley JM, Moore JP, Sodroski J, Sullivan N, Sawyer LS, Hendry RM, Yang WP, Barbas CF 3rd, Burton DR.

J Immunol. 1995 Jan 15;154(2):893-906.

PMID:
7529290
8.

Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains.

Xiang SH, Wang L, Abreu M, Huang CC, Kwong PD, Rosenberg E, Robinson JE, Sodroski J.

Virology. 2003 Oct 10;315(1):124-34.

9.

Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci.

He Y, Honnen WJ, Krachmarov CP, Burkhart M, Kayman SC, Corvalan J, Pinter A.

J Immunol. 2002 Jul 1;169(1):595-605.

11.
13.

Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120.

Bagley J, Dillon PJ, Rosen C, Robinson J, Sodroski J, Marasco WA.

Mol Immunol. 1994 Oct;31(15):1149-60.

PMID:
7935503
14.

Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.

Nakamura GR, Byrn R, Wilkes DM, Fox JA, Hobbs MR, Hastings R, Wessling HC, Norcross MA, Fendly BM, Berman PW.

J Virol. 1993 Oct;67(10):6179-91.

16.

Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction.

McKeating JA, Thali M, Furman C, Karwowska S, Gorny MK, Cordell J, Zolla-Pazner S, Sodroski J, Weiss RA.

Virology. 1992 Sep;190(1):134-42.

PMID:
1382339
19.

Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.

Richardson TM Jr, Stryjewski BL, Broder CC, Hoxie JA, Mascola JR, Earl PL, Doms RW.

J Virol. 1996 Feb;70(2):753-62.

20.

Non-covalent complexes of HIV gp120 with CD4 and/or mAbs enhance activation of gp120-specific T clones and provide intermolecular help for anti-CD4 antibody production.

Manca F, Seravalli E, Valle MT, Fenoglio D, Kunkl A, Li Pira G, Zolla-Pazner S, Celada F.

Int Immunol. 1993 Sep;5(9):1109-17.

PMID:
7902128

Supplemental Content

Support Center